BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T-cell lymphoma.

Histologic examination and immunophenotyping of biopsy specimens confirmed a stage V (b) T-cell malignant lymphoma.

TREATMENT AND OUTCOME: Clinical remission was attained by use of 2 chemotherapy cycles, followed by an allogeneic hematopoietic cell transplant performed at 18 weeks after diagnosis.

Remission has been confirmed by normal results of serum thymidine kinase assays and the absence of peripheral blood clonal T-cell receptor gene rearrangements.

Outcome of allogeneic hematopoietic cell transplantation in dogs can be excellent because of improved donor-recipient selection by use of molecular dog leukocyte antigen typing, compared with early attempts, and better prevention of graft versus host disease, better supportive care, and substitution of peripheral blood mononuclear cells for bone marrow.

[MeSH-major] Dog Diseases / therapy. Hematopoietic Stem Cell Transplantation / veterinary. Histocompatibility Antigens / immunology. Immunosuppression / veterinary. Lymphoma, T-Cell / veterinary

[MeSH-minor] Animals. Cyclosporine / pharmacology. Dogs. Graft Survival. Granulocyte Colony-Stimulating Factor / pharmacology. Hematopoietic Stem Cell Mobilization. Histocompatibility Testing. Male. Transplantation Chimera. Transplantation, Homologous / veterinary. Treatment Outcome. Whole-Body Irradiation / veterinary

Hazardous Substances Data Bank. CYCLOSPORIN A .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16506937.001).

[ISSN] 0003-1488

[Journal-full-title] Journal of the American Veterinary Medical Association

[ISO-abbreviation] J. Am. Vet. Med. Assoc.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Histocompatibility Antigens; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83HN0GTJ6D / Cyclosporine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.

We evaluated the efficacy and safety of patient-specific immunotherapy with mitumprotimut-T idiotype keyhole limpet hemocyanin and granulocyte-monocyte colony-stimulating factor (GM-CSF) following rituximab in patients with follicular B-cell lymphoma.

Patients with previously untreated or relapsed/refractory CD20+ follicular lymphoma received 4 weekly infusions of rituximab and those with a complete response (CR), partial response (PR), or stable disease received mitumprotimut-T and GM-CSF injections subcutaneously.

Among 103 patients treated with rituximab, 92 (54 relapsed/refractory and 38 previously untreated) received mitumprotimut-T/GM-CSF; median age was 53 years, 91% had stage III to IV disease, and 59% had failed earlier therapy.

[MeSH-major] Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Immunotherapy. Lymphoma, B-Cell / therapy. Lymphoma, Follicular / therapy. Recombinant Fusion Proteins / administration & dosage

Genetic Alliance. consumer health - Follicular Lymphoma.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. RITUXIMAB .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20145546.001).

[ISSN] 1537-4513

[Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)

[ISO-abbreviation] J. Immunother.

[Language] eng

[Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antigens, Neoplasm; 0 / Immunoglobulin Idiotypes; 0 / Recombinant Fusion Proteins; 0 / Recombinant Proteins; 4F4X42SYQ6 / Rituximab; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 9013-72-3 / Hemocyanin; FV4Y0JO2CX / keyhole-limpet hemocyanin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms.

IPSID is a variant of the B-cell lymphoma of mucosa-associated lymphoid tissue (MALT), which involves mainly the proximal small intestine resulting in malabsorption, diarrhea, and abdominal pain.

IPSID lymphomas reveal excessive plasma cell differentiation and produce truncated alpha heavy chain proteins lacking the light chains as well as the first constant domain.

Early-stage IPSID responds to antibiotics (30%-70% complete remission).

Most untreated IPSID patients progress to lymphoplasmacytic and immunoblastic lymphoma invading the intestinal wall and mesenteric lymph nodes, and may metastasize to a distant organ.

IPSID lymphoma shares clinical, morphologic, and molecular features with MALT lymphoma, lymphoplasmacytic lymphoma, and plasma cell neoplasms.

[MeSH-major] Campylobacter Infections. Campylobacter jejuni. Immunoproliferative Small Intestinal Disease. Lymphoma, B-Cell, Marginal Zone. Plasma Cells / immunology

[MeSH-minor] Adolescent. Adult. Africa. B-Cell-Specific Activator Protein / genetics. B-Cell-Specific Activator Protein / immunology. Child. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 9 / genetics. Chromosomes, Human, Pair 9 / immunology. Female. Humans. Immunoglobulin Light Chains / genetics. Immunoglobulin Light Chains / immunology. Immunoglobulin Variable Region / genetics. Immunoglobulin Variable Region / immunology. Immunoglobulin alpha-Chains / genetics. Immunoglobulin alpha-Chains / immunology. Intestine, Small / immunology. Intestine, Small / pathology. Lymph Nodes / immunology. Lymph Nodes / pathology. Male. Mesentery / immunology. Mesentery / pathology. Middle East. Sequence Deletion / genetics. Sequence Deletion / immunology. Translocation, Genetic / genetics. Translocation, Genetic / immunology

MedlinePlus Health Information. consumer health - Campylobacter Infections.

The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for immunoproliferative small intestinal disease .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15542584.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin Variable Region; 0 / Immunoglobulin alpha-Chains; 0 / PAX5 protein, human

[Number-of-references] 78

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

PURPOSE: This is a multicenter phase I/II dose-finding study in relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating veltuzumab, a humanized anti-CD20 antibody with structure-function differences from chimeric rituximab.

PATIENTS AND METHODS: Eighty-two patients (median age, 64 years; 79% stage III/IV, one to nine prior treatments) received four once-weekly doses of 80 to 750 mg/m(2) of veltuzumab and were assessed for safety, efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity.

In follicular lymphoma, 24 (44%) of 55 patients had objective responses (OR), with 15 (27%) complete responses (CRs) or CRs unconfirmed (CRus) by International Working Group criteria, and with some responses occurring despite two to five prior rituximab-containing regimens, less favorable prognosis (elevated lactate dehydrogenase, tumors > 5 cm, and Follicular Lymphoma International Prognostic Index > or = 2), and at all dose levels.

In marginal zone lymphoma, five (83%) of six patients had ORs, with two CRs/CRus (33%), and in diffuse large B-cell lymphoma, three (43%) of seven patients achieved partial responses.

[MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy

[MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Fever / chemically induced. Headache / chemically induced. Humans. Kaplan-Meier Estimate. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Male. Middle Aged. Pruritus / chemically induced. Recurrence. Treatment Outcome

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19451441.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Databank-accession-numbers] ClinicalTrials.gov/ NCT00285428/ NCT00596804

[Grant] United Kingdom / Medical Research Council / / MC/ U132670597

[Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / veltuzumab

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database.

Pulmonary marginal zone lymphoma is a rare disease arising from bronchial-associated lymphoid tissue (BALT).

There is limited information on clinical presentation, natural history and treatment of this type of lymphoma.

We conducted a retrospective review of patients with biopsy-proven BALT lymphoma treated at our institution and patients from the surveillance epidemiology and end results (SEER) database.

Twenty-one patients (median age 57) with disease stage IE (n = 10) and IV (n = 11), were treated at our institution.

We identified 326 patients (59% females and 41% males; median age 68 [30 to 85) with BALT lymphoma in the SEER database.

Fifty-five per cent had stage IE, 10% stage IIE, 3% stage IIIE, and 22% stage IV disease.

[MeSH-major] Lung Neoplasms. Lymphoma, B-Cell, Marginal Zone

MedlinePlus Health Information. consumer health - Lung Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18604720.001).

[ISSN] 1029-2403

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Grant] United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Losing B cell identity.

The transcription factor Pax5 is essential for the initial commitment of hematopoietic progenitors to the B cell lineage.

Recently, our understanding of the lineage commitment process has been extended with the finding that Pax5 is also continuously required throughout B cell development to reinforce commitment, as inactivation of Pax5 in mature B cells results in their de-differentiation to a progenitor stage that is capable of multi-lineage potential.

The reliance of B cell identity on a single gene is not without its problems as the loss of Pax5 results in B cell malignancies in mouse models and mutation in human PAX5 is the most-common genetic lesion in acute lymphoblastic leukemia.

[MeSH-major] B-Cell-Specific Activator Protein / physiology. B-Lymphocytes / cytology. Gene Expression Regulation

[MeSH-minor] Animals. Cell Differentiation. Cell Lineage. Disease Models, Animal. Hematopoietic Stem Cells / cytology. Humans. Mice. Models, Biological. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18293359.001).

[ISSN] 1521-1878

[Journal-full-title] BioEssays : news and reviews in molecular, cellular and developmental biology

[ISO-abbreviation] Bioessays

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / PAX5 protein, human

[Number-of-references] 34

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Splenectomy--a therapeutic option in splenic marginal zone cell lymphoma.

Lymph node and bone marrow biopsy together with flowcytometry established the diagnosis of Malignant non-Hodgkin Lymphoma--Atypical Splenic Marginal Zone B-cell lymphoma (aberrant expression of CD5) stage IVB, with leukemic picture, complicated with autoimmune hemolytic anemia with highly positive Coombs' tests.

[MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / surgery. Splenectomy. Splenic Neoplasms / pathology. Splenic Neoplasms / surgery

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20067170.001).

[ISSN] 1220-4749

[Journal-full-title] Romanian journal of internal medicine = Revue roumaine de médecine interne

[ISO-abbreviation] Rom J Intern Med

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Romania

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Macrophage inflammatory protein-1 alpha (MIP-1alpha) is a member of the CC chemokine family and is primarily associated with cell adhesion and migration.

MIP-1alpha protein levels were elevated in the bone marrow plasma of MM patients and correlated with disease stage and activity.

Genetic Alliance. consumer health - Multiple myeloma.

MedlinePlus Health Information. consumer health - Multiple Myeloma.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16263571.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Carrier Proteins; 0 / Chemokine CCL3; 0 / Chemokine CCL4; 0 / Macrophage Inflammatory Proteins; 0 / Membrane Glycoproteins; 0 / RANK Ligand; 0 / Receptor Activator of Nuclear Factor-kappa B; 0 / TNFRSF11A protein, human; 0 / TNFSF11 protein, human; 0 / Tnfrsf11a protein, mouse; 0 / Tnfsf11 protein, mouse

[Number-of-references] 44

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia.

ZAP-70 and CD38 expression can identify B-cell chronic lymphocytic leukemia with an inferior clinical outcome.

Forty-one untreated and stage A patients, either ZAP-70(+)CD38(+) or ZAP-70(-)CD38(-), were tested to determine the MDR1 status.

[MeSH-major] Antigens, CD38 / metabolism. Drug Resistance, Multiple. Gene Expression Regulation, Leukemic. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Membrane Glycoproteins / metabolism. P-Glycoprotein / metabolism. ZAP-70 Protein-Tyrosine Kinase / metabolism

Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

Genetic Alliance. consumer health - Leukemia, B-cell, chronic.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Leuk Lymphoma. 2007 Aug;48(8):1468-9 [17701575.001]

(PMID = 17701587.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Membrane Glycoproteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic factors for classifying extranodal NK/T cell lymphoma, nasal type, as lymphoid neoplasia.

This study evaluated the applicability of prognostic factors commonly used for diagnosis of classical lymphoma outcomes to extranodal NK/T cell lymphoma, nasal type (NTCL).

RLDH was associated with stage (I-II vs. III-IV), lymph node involvement (LNI), and International Prognostic Index score (<2 vs. > or =2).

Poor performance status and advanced stage were common in patients with local tumor invasiveness (LTI).

In multivariate analysis, the predictive values of LDH level, B symptom, performance status, and stage remained significant whereas those of LTI and LNI did not.

[MeSH-major] Killer Cells, Natural / immunology. Lymphoma, T-Cell / classification. Nose Neoplasms / classification

MedlinePlus Health Information. consumer health - Nasal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17598834.001).

[ISSN] 0902-4441

[Journal-full-title] European journal of haematology

[ISO-abbreviation] Eur. J. Haematol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Denmark

[Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Mycosis fungoides in the pediatric population: report from an international Childhood Registry of Cutaneous Lymphoma.

BACKGROUND/OBJECTIVES: There are limited data on the clinical presentation and progression of pediatric cutaneous lymphoma.

The most common MF presentation was patch stage (68%), followed by hypopigmentation (59%) and plaque stage disease (50%).

All patients presented with early-stage disease and received skin-directed therapy (topical steroids, 73%; light therapy, 54%; or combination therapy, 35%).

CONCLUSIONS: Pediatric patients with MF present in the first decade of life, with early-stage disease and unusual forms such as hypopigmented variant.

Further patient enrollment will provide information regarding natural history, treatment response, and overall prognosis of pediatric cutaneous T-cell lymphoma (CTCL).

[MeSH-major] Lymphoma, T-Cell, Cutaneous / epidemiology. Mycosis Fungoides / epidemiology. Skin Neoplasms / epidemiology

Genetic Alliance. consumer health - Mycosis fungoides.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20128983.001).

[ISSN] 1203-4754

[Journal-full-title] Journal of cutaneous medicine and surgery

[ISO-abbreviation] J Cutan Med Surg

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma.

BACKGROUND: The results of CHOP-21 (cyclophosphamide, doxorubicin, vincristine and prednisone given every 21 days) for the treatment of aggressive B-cell lymphoma have recently been improved by the addition of rituximab and by increasing the dose density.

PATIENTS AND METHODS: We present our experience with R-CHOP-14 in a retrospective single-centre review of 50 patients consecutively treated for aggressive B-cell lymphoma.

Stage III-IV was present in 62% of the patients and international prognostic index was high-to-intermediate risk or high risk in 32% of the patients.

CONCLUSIONS: In our experience the combination of RCHOP- 14 is highly effective in patients with aggressive B-cell lymphoma.

[MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / therapy

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]

[Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]

[Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]

[Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]

[Cites] J Clin Oncol. 1984 Nov;2(11):1281-8 [6387060.001]

[Cites] Acta Haematol. 2006;115(1-2):22-7 [16424645.001]

[Cites] Hematol Oncol. 2008 Mar;26(1):27-32 [17868190.001]

[Cites] Leuk Lymphoma. 2005 Apr;46(4):541-7 [16019482.001]

[Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]

[Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]

[Cites] N Engl J Med. 1992 Nov 5;327(19):1342-9 [1383819.001]

[Cites] Haematologica. 2006 Apr;91(4):496-502 [16537117.001]

[Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]

[Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]

[Cites] Lancet Oncol. 2008 Feb;9(2):105-16 [18226581.001]

(PMID = 19776000.001).

[ISSN] 1699-3055

[Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

[ISO-abbreviation] Clin Transl Oncol

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] Italy

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

RESULTS: From a total of 98 patients, there were 81 (82.6%) epithelial, 12 (12.2%) germ cell, 4 (4.1%) granulosa cell tumors, and one case of lymphoma.

Stage III was the most common stage (44.9%).

The most important prognostic factors were the initial stage (p=0.034), and the extent of surgical procedure (p=0.045).

[MeSH-major] Neoplasms, Germ Cell and Embryonal / drug therapy. Ovarian Neoplasms / drug therapy

Genetic Alliance. consumer health - Ovarian cancer.

Genetic Alliance. consumer health - Ovarian epithelial cancer.

MedlinePlus Health Information. consumer health - Ovarian Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19082223.001).

[ISSN] 0379-5284

[Journal-full-title] Saudi medical journal

[ISO-abbreviation] Saudi Med J

[Language] eng

[Publication-type] Journal Article; Multicenter Study

[Publication-country] Saudi Arabia

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.

PURPOSE: High-dose chemotherapy (HDCT) followed by autologous stem-cell transplantation (PBSCT) has become the standard treatment for patients with relapsed Hodgkin's lymphoma (HL).

Patients with stage IV, early relapse, multiple relapse, anemia, or B symptoms had a higher risk of recurrence (P < .001).

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Neoplasm Recurrence, Local / drug therapy

[MeSH-minor] Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / adverse effects. Humans. Kaplan-Meier Estimate. Methotrexate / administration & dosage. Methotrexate / adverse effects. Peripheral Blood Stem Cell Transplantation. Prognosis

MedlinePlus Health Information. consumer health - Hodgkin Disease.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. DEXAMETHASONE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. METHOTREXATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20975066.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Targeted deletion of p73 in mice reveals its role in T cell development and lymphomagenesis.

We show here that p73 acts as a T cell-specific tumor suppressor in a genetically defined mouse model, and that concomitant ablation of p53 and p73 predisposes mice to an increased incidence of thymic lymphomas compared to the loss of p53 alone.

Our results demonstrate a causal role for loss of p73 in progression of T cell lymphomas to the stage of aggressive, disseminated disease.

We provide evidence that tumorigenesis in mice lacking p53 and p73 proceeds through mechanisms involving altered patterns of gene expression, defects in early T cell development, impaired apoptosis, and the ensuing accumulation of chromosomal aberrations.

Collectively, our data imply that tumor suppressive properties of p73 are highly dependent on cellular context, wherein p73 plays a major role in T cell development and neoplasia.

[MeSH-major] DNA-Binding Proteins / genetics. Gene Deletion. Lymphoma / metabolism. Nuclear Proteins / genetics. T-Lymphocytes / cytology. Tumor Suppressor Proteins / genetics

MedlinePlus Health Information. consumer health - Lymphoma.

COS Scholar Universe. author profiles.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nature. 2000 Mar 2;404(6773):99-103 [10716451.001]

[Cites] Mutat Res. 2009 Jan 15;660(1-2):22-32 [19000702.001]

[Cites] Nature. 2002 Apr 4;416(6880):560-4 [11932750.001]

[Cites] Cell. 2002 Apr;109 Suppl:S45-55 [11983152.001]

[Cites] Nat Rev Cancer. 2002 Aug;2(8):605-15 [12154353.001]

[Cites] Int J Cancer. 2002 Nov 1;102(1):15-9 [12353228.001]

[Cites] J Biol Chem. 2002 Oct 18;277(42):39156-62 [12114514.001]

[Cites] Nat Immunol. 2003 Jun;4(6):533-9 [12717433.001]

[Cites] Mol Cell Biol. 2003 Aug;23(16):5540-55 [12897129.001]

[Cites] Leukemia. 2003 Sep;17(9):1845-50 [12970785.001]

[Cites] Clin Cancer Res. 2003 Nov 15;9(15):5642-51 [14654547.001]

[Cites] Clin Cancer Res. 2004 Jan 15;10(2):626-33 [14760085.001]

[Cites] Nat Rev Immunol. 2004 Apr;4(4):278-89 [15057786.001]

[Cites] Cancer Res. 2004 Apr 1;64(7):2449-60 [15059898.001]

[Cites] Cancer Genet Cytogenet. 2004 May;151(1):36-51 [15120909.001]

[Cites] Carcinogenesis. 2004 Jun;25(6):1069-75 [14754877.001]

[Cites] Cancer Cell. 2004 Jul;6(1):85-9 [15261144.001]

[Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]

[Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]

[Cites] Mol Carcinog. 1995 Sep;14(1):16-22 [7546219.001]

[Cites] Genes Dev. 1996 Mar 1;10(5):553-65 [8598286.001]

[Cites] Genes Dev. 1996 Aug 15;10(16):2038-54 [8769647.001]

[Cites] Genes Dev. 1996 Aug 15;10(16):2055-66 [8769648.001]

[Cites] Cell. 1997 Aug 22;90(4):809-19 [9288759.001]

[Cites] Nature. 1997 Sep 11;389(6647):191-4 [9296498.001]

[Cites] Cancer Res. 1997 Oct 1;57(19):4408-13 [9331104.001]

[Cites] Cancer Res. 1999 Jul 15;59(14):3352-6 [10416592.001]

[Cites] Immunity. 1999 Jul;11(1):91-101 [10435582.001]

[Cites] Cancer Res. 2004 Dec 15;64(24):8882-90 [15604248.001]

[Cites] Cancer Cell. 2005 Apr;7(4):363-73 [15837625.001]

[Cites] Mutat Res. 2005 Aug 25;576(1-2):4-21 [16038709.001]

[Cites] Oncogene. 2005 Aug 18;24(35):5521-4 [16007185.001]

[Cites] Cancer Cell. 2006 Feb;9(2):109-20 [16473278.001]

[Cites] Nat Rev Immunol. 2007 Jan;7(1):64-75 [17170755.001]

[Cites] Nat Rev Cancer. 2007 Mar;7(3):165-8 [17332760.001]

[Cites] Oncogene. 2007 Aug 9;26(36):5280-9 [17325664.001]

[Cites] Mol Cell. 2007 Aug 17;27(4):647-59 [17707235.001]

[Cites] Genet Med. 2007 Sep;9(9):585-95 [17873646.001]

[Cites] Blood. 2007 Nov 1;110(9):3102-11 [17656647.001]

[Cites] Genes Dev. 2008 Oct 1;22(19):2677-91 [18805989.001]

[Cites] EMBO J. 2002 Mar 15;21(6):1447-55 [11889050.001]

(PMID = 19907659.001).

[ISSN] 1932-6203

[Journal-full-title] PloS one

[ISO-abbreviation] PLoS ONE

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73

[Other-IDs] NLM/ PMC2771421

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions.

Patients' characteristics, including age, sex, stage of the underlying disease (complete or partial remission), diagnosis, previously administered radio/chemotherapy regimens, time-lapse from last chemotherapy before mobilization and mobilization schedule (including dose of GF) were considered as possibly predictive of poor or failed mobilization.

Therefore, a patient who fails a first mobilization (and when an HLA-compatible related on unrelated donor is not available) could undergo a second attempt either with different mobilization schedule or by using different GF, such as stem cell factor, growth hormone (GH), or more recently newly introduced drugs such as AMD3100, alone or in combination with rHuG- or -rHuGM-CSF.

[MeSH-major] Neoplasms / surgery. Peripheral Blood Stem Cell Transplantation / methods

[MeSH-minor] Adult. Antigens, CD34 / blood. Follow-Up Studies. Hematopoiesis. Hematopoietic Stem Cell Mobilization / methods. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / surgery. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Leukemia, Myeloid, Acute / surgery. Lymphoma, Non-Hodgkin / surgery. Multiple Myeloma / surgery. Retrospective Studies. Survival Analysis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19540167.001).

[ISSN] 1473-0502

[Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

[ISO-abbreviation] Transfus. Apher. Sci.

[Language] eng

[Publication-type] Journal Article; Multicenter Study

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, CD34

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Msh6 protects mature B cells from lymphoma by preserving genomic stability.

Most human B-cell non-Hodgkin's lymphomas arise from germinal centers.

Reminiscent of the neoplasms arising in patients with Lynch syndrome III, mice deficient in MSH6 die prematurely of lymphoma.

In this study, we characterized the B-cell tumors in MSH6-deficient mice and describe their histological, immunohistochemical, and molecular features, which include moderate microsatellite instability.

Based on histological markers and gene expression, the tumor cells seem to be at or beyond the germinal center stage.

COS Scholar Universe. author profiles.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Rev Immunol. 2002 Dec;2(12):920-32 [12461565.001]

[Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4126-31 [12651942.001]

[Cites] Blood. 2003 May 1;101(9):3574-80 [12511417.001]

[Cites] Immunol Rev. 2003 Aug;194:177-95 [12846815.001]

[Cites] Cancer Res. 2003 Jul 15;63(14):3894-8 [12873980.001]

[Cites] Curr Opin Genet Dev. 1999 Feb;9(1):89-96 [10072354.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6850-5 [10359802.001]

[Cites] Immunity. 1999 Sep;11(3):309-16 [10514009.001]

[Cites] Am J Hum Genet. 1999 Nov;65(5):1291-8 [10521294.001]

[Cites] Nature. 2004 Dec 2;432(7017):635-9 [15577913.001]

[Cites] Nat Rev Cancer. 2005 Apr;5(4):251-62 [15803153.001]

[Cites] Cancer Res. 2005 Apr 1;65(7):2626-35 [15805259.001]

[Cites] J Pathol. 2005 May;206(1):76-86 [15772984.001]

[Cites] Cancer Cell. 2005 May;7(5):445-55 [15894265.001]

[Cites] Annu Rev Biochem. 2005;74:681-710 [15952900.001]

[Cites] Oncogene. 2005 May 19;24(22):3544-53 [15688022.001]

[Cites] Mol Carcinog. 2005 Dec;44(4):285-92 [16240453.001]

[Cites] Fam Cancer. 2005;4(4):323-33 [16341812.001]

[Cites] J Immunol. 2005 Dec 15;175(12):7837-47 [16339519.001]

[Cites] J Exp Med. 2006 Jan 23;203(1):63-72 [16380510.001]

[Cites] Chem Rev. 2006 Feb;106(2):302-23 [16464007.001]

[Cites] Carcinogenesis. 2006 Apr;27(4):682-92 [16332722.001]

[Cites] Oncologist. 2006 Apr;11(4):384-92 [16614234.001]

[Cites] Oncogene. 2006 Apr 20;25(17):2531-6 [16331258.001]

[Cites] Nat Rev Mol Cell Biol. 2006 May;7(5):335-46 [16612326.001]

[Cites] FEBS J. 2006 Oct;273(19):4504-15 [16956364.001]

[Cites] Curr Biol. 2006 Sep 19;16(18):R808-10 [16979551.001]

[Cites] Clin Cancer Res. 2006 Nov 1;12(21):6379-85 [17085649.001]

[Cites] Science. 2007 Jan 26;315(5811):528-31 [17185562.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1616-20 [17251349.001]

[Cites] Cancer Res. 2007 Mar 15;67(6):2439-47 [17363561.001]

[Cites] Lancet Neurol. 2007 Apr;6(4):340-51 [17362838.001]

[Cites] Int Immunol. 2007 Apr;19(4):545-56 [17329233.001]

[Cites] Mol Cell. 2007 May 25;26(4):565-78 [17531814.001]

[Cites] Mol Cell. 2007 May 25;26(4):579-92 [17531815.001]

[Cites] Clin Genet. 2007 Jun;71(6):499-500 [17539898.001]

[Cites] Nat Immunol. 2007 Jul;8(7):705-14 [17558410.001]

[Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10956-61 [17573527.001]

[Cites] Nucleic Acids Res. 2007;35(12):4114-23 [17567610.001]

[Cites] J Exp Med. 2007 Aug 6;204(8):1989-98 [17664295.001]

[Cites] Nat Immunol. 2007 Oct;8(10):1132-9 [17828269.001]

[Cites] J Immunol. 2007 Nov 15;179(10):6808-19 [17982071.001]

[Cites] Carcinogenesis. 2007 Dec;28(12):2427-33 [17804422.001]

[Cites] J Immunol. 2003 Sep 15;171(6):2889-95 [12960311.001]

[Cites] Mol Carcinog. 2003 Dec;38(4):155-9 [14639654.001]

[Cites] Nat Immunol. 2004 Feb;5(2):224-9 [14716311.001]

[Cites] Gastroenterology. 2004 Jul;127(1):17-25 [15236168.001]

[Cites] J Exp Med. 2004 Jul 5;200(1):47-59 [15238604.001]

[Cites] J Exp Med. 2004 Jul 5;200(1):61-8 [15238605.001]

[Cites] Am J Med Genet C Semin Med Genet. 2004 Aug 15;129C(1):91-9 [15264277.001]

[Cites] Cancer Cell. 2004 Aug;6(2):139-50 [15324697.001]

[Cites] Nat Immunol. 2004 Nov;5(11):1117-23 [15489857.001]

[Cites] Gene. 1994 Sep 30;147(2):157-60 [7926794.001]

[Cites] Curr Biol. 1994 Jul 1;4(7):573-83 [7953531.001]

[Cites] Anticancer Res. 1994 Jul-Aug;14(4B):1635-9 [7979199.001]

[Cites] Science. 1995 Jun 2;268(5215):1336-8 [7761852.001]

[Cites] Cell. 1995 Jul 28;82(2):321-30 [7628020.001]

[Cites] Nat Genet. 1995 Sep;11(1):64-70 [7550317.001]

[Cites] Cancer Res. 1996 Aug 15;56(16):3842-9 [8706033.001]

[Cites] Nat Genet. 1996 Nov;14(3):312-5 [8896561.001]

[Cites] Blood. 1997 Apr 1;89(7):2276-82 [9116269.001]

[Cites] J Biol Chem. 1997 Oct 17;272(42):26382-7 [9334212.001]

[Cites] Cell. 1997 Nov 14;91(4):467-77 [9390556.001]

[Cites] Genetics. 1998 Apr;148(4):1637-46 [9560383.001]

[Cites] Blood. 1998 Jun 15;91(12):4677-85 [9616165.001]

[Cites] Science. 1998 Jun 12;280(5370):1750-2 [9624052.001]

[Cites] Leukemia. 1998 Jun;12(6):845-59 [9639410.001]

[Cites] Immunity. 1998 Jul;9(1):127-34 [9697842.001]

[Cites] Eur J Hum Genet. 2008 Jan;16(1):62-72 [17851451.001]

[Cites] Nat Rev Immunol. 2008 Jan;8(1):22-33 [18097447.001]

[Cites] Nat Genet. 2008 Jan;40(1):108-12 [18066064.001]

[Cites] Nature. 2008 Feb 14;451(7180):841-5 [18273020.001]

[Cites] Annu Rev Immunol. 2008;26:481-511 [18304001.001]

[Cites] Annu Rev Immunol. 2008;26:261-92 [18370922.001]

[Cites] Biochemistry. 2008 Jun 10;47(23):6199-207 [18484749.001]

[Cites] PLoS Genet. 2008 Jun;4(6):e1000092 [18551179.001]

[Cites] J Immunol. 2008 Jul 15;181(2):1299-306 [18606684.001]

[Cites] DNA Repair (Amst). 2008 Aug 2;7(8):1392-8 [18562254.001]

[Cites] Oncogene. 2008 Aug 7;27(34):4752-6 [18408759.001]

[Cites] Hum Genet. 2008 Sep;124(2):105-22 [18709565.001]

[Cites] J Exp Med. 2008 Sep 1;205(9):1949-57 [18678733.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16248-53 [18854411.001]

[Cites] DNA Repair (Amst). 2009 Jan 1;8(1):137-41 [18952008.001]

[Cites] Genet Med. 2009 Jan;11(1):42-65 [19125127.001]

[Cites] Blood. 2009 Jul 16;114(3):547-54 [19478044.001]

[Cites] J Immunol. 2009 Sep 1;183(5):3188-94 [19648273.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18698-703 [19837692.001]

[Cites] Nat Rev Clin Oncol. 2010 Apr;7(4):197-208 [20177404.001]

[Cites] Haematologica. 2010 May;95(5):841-4 [20015892.001]

[Cites] Nat Genet. 1999 Nov;23(3):359-62 [10545954.001]

[Cites] J Exp Med. 2000 Feb 7;191(3):579-84 [10662804.001]

[Cites] Blood. 2000 Mar 1;95(5):1767-72 [10688836.001]

[Cites] Lab Invest. 2000 Feb;80(2):159-69 [10701686.001]

[Cites] Cancer Res. 2000 Feb 15;60(4):803-7 [10706084.001]

[Cites] Blood. 2000 Apr 15;95(8):2719-21 [10753856.001]

[Cites] Leuk Res. 2000 Aug;24(8):719-32 [10936424.001]

[Cites] Cell. 2000 Sep 1;102(5):553-63 [11007474.001]

[Cites] Cell. 2000 Sep 1;102(5):565-75 [11007475.001]

[Cites] J Exp Med. 2000 Dec 18;192(12):1833-40 [11120779.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]

[Cites] Nature. 2001 Jul 19;412(6844):341-6 [11460166.001]

[Cites] Cancer Res. 2001 Nov 1;61(21):7934-42 [11691815.001]

[Cites] Am J Hum Genet. 2002 Jan;70(1):26-37 [11709755.001]

[Cites] Bioinformatics. 2002 Jan;18(1):207-8 [11836235.001]

[Cites] J Exp Med. 2002 May 6;195(9):1187-92 [11994423.001]

[Cites] J Exp Med. 2002 May 6;195(9):1193-8 [11994424.001]

[Cites] Blood. 2002 Jul 1;100(1):246-58 [12070034.001]

(PMID = 20934970.001).

[ISSN] 1525-2191

[Journal-full-title] The American journal of pathology

[ISO-abbreviation] Am. J. Pathol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P30CA013330; United States / NCI NIH HHS / CA / CA072649-13; United States / NCI NIH HHS / CA / R01-CA72649; United States / NCI NIH HHS / CA / R01 CA072649-13; United States / NCI NIH HHS / CA / R01 CA093484; United States / NCI NIH HHS / CA / R01-CA102705; United States / NCI NIH HHS / CA / R01 CA076329; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / R01 CA102705; United States / NCI NIH HHS / CA / R01 CA102705-08; United States / NCI NIH HHS / CA / R01-CA76329; United States / NIGMS NIH HHS / GM / T32 GM007288; United States / NCI NIH HHS / CA / R01 CA072649; United States / NCI NIH HHS / CA / R01-CA93484; United States / NCI NIH HHS / CA / CA102705-08; United States / NCI NIH HHS / CA / P30 CA013330; United States / NIGMS NIH HHS / GM / T32-GM007288

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.5 / Cytidine Deaminase

[Other-IDs] NLM/ PMC2966815

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

With the growing use of potent immunosuppressive purine analogues, fludarabine, pentostatin and cladibrine, and anti-T and anti-B cell antibodies, such as rituximab and campath, in the management of lymphoreticular malignancies, in combination with increasing emphasis on dose intensity, the number of patients at risk has almost reached levels encountered in recipients of allogenic stem cell grafts as a consequence of long-lasting deficiencies in the cellular immunity.

The spectrum of opportunistic pathogens are shifting as anti-leukemic and anti-lymphoma therapy become more intensive and bone marrow transplant practices evolve.

During the past decades we have even observed an increased incidence of invasive fungal infections in patients who are not in an end stage of their underlying disease.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16864116.001).

[ISSN] 1825-151X

[Journal-full-title] Reviews in clinical and experimental hematology

[ISO-abbreviation] Rev Clin Exp Hematol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Italy

[Chemical-registry-number] 0 / Immunosuppressive Agents

[Number-of-references] 85

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma.

PURPOSE: It is uncertain whether the tumor burden as assessed using FDG-PET has prognostic significance in newly diagnosed diffuse large B-cell lymphoma (DLBCL).

MATERIALS AND METHODS: Forty-two DLBCL patients (age, 57.4 ± 15.5 years; male/female = 25/17; stage I/II/III/IV=5/17/10/10) who underwent FDG-PET before chemotherapy were enrolled.

Among six variables [Ann Arbor stage, %Ki-67 expression, International Prognostic Index (IPI), MaxSUV, greatest diameter, and SIMaxSUV] investigated, only SIMaxSUV was found to be a single determinant of progression-free and overall survivals by multivariate analyses (p < 0.05).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 24899936.001).

[ISSN] 1869-3474

[Journal-full-title] Nuclear medicine and molecular imaging

[ISO-abbreviation] Nucl Med Mol Imaging

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Other-IDs] NLM/ PMC4042962

[Keywords] NOTNLM ; FDG-PET / Greatest diameter / Lymphoma / Prognosis / SUV / Size-incorporated maxSUV

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab.

We have treated 67 patients, 8 non-Hodgkin's lymphoma and 59 chronic lymphocytic leukemia (CLL) with campath.

[MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Cell Count. Drug Administration Schedule. Female. Humans. Immune System / cytology. Male. Middle Aged. Remission Induction. Treatment Outcome

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentOn] Haematologica. 2007 Jun;92(6):784-94 [17550851.001]

(PMID = 18245646.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Comment; Letter

[Publication-country] Italy

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia.

Statins and non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed medications.

In vitro studies suggest that statins and NSAIDs may have potential as anticancer therapies in low-grade non-Hodgkin lymphomas including chronic lymphocytic leukemia (CLL), and a recent observational study found statin use was associated with improved event free survival in patients with follicular lymphoma.

We therefore conducted an observational cohort study of 686 patients with newly diagnosed Rai stage 0 CLL to evaluate whether statin or NSAID use was related to their clinical outcome or influenced the efficacy of rituximab therapy.

Although previous studies suggested statins may improve event free survival among patients with follicular lymphoma, we find no impact of statins on time to initial therapy in this large study of patients with Rai stage 0 CLL.

Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

MedlinePlus Health Information. consumer health - Statins.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. RITUXIMAB .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Br J Haematol. 2007 Nov;139(3):398-404 [17910629.001]

[Cites] Leuk Lymphoma. 2007 Dec;48(12):2412-7 [18067017.001]

[Cites] Cancer Immunol Immunother. 2008 Mar;57(3):347-58 [17668203.001]

[Cites] Leuk Lymphoma. 2008 Jan;49(1):49-56 [18203011.001]

[Cites] Invest New Drugs. 2008 Apr;26(2):139-49 [18094935.001]

[Cites] PLoS Med. 2008 Mar 25;5(3):e64 [18366248.001]

[Cites] Atherosclerosis. 2008 Apr;197(2):829-39 [17826781.001]

[Cites] Br J Haematol. 2008 May;141(5):615-21 [18373706.001]

[Cites] Br J Haematol. 2008 May;141(5):607-14 [18384436.001]

[Cites] Ann Pharmacother. 2008 Sep;42(9):1208-15 [18648016.001]

[Cites] J Clin Oncol. 2008 Nov 20;26(33):5486; author reply 5486 [18936467.001]

[Cites] Leukemia. 2008 Dec;22(12):2184-92 [18784741.001]

[Cites] N Engl J Med. 2009 Jan 8;360(2):192; author reply 193 [19129537.001]

[Cites] Lancet. 2009 Apr 11;373(9671):1301-9 [19328542.001]

[Cites] J Clin Oncol. 2010 Jan 20;28(3):412-7 [20008638.001]

[Cites] JAMA. 2002 Jan 16;287(3):337-44 [11790213.001]

[Cites] Br J Haematol. 2001 Dec;115(4):854-61 [11843819.001]

[Cites] Cancer Res. 2002 Oct 15;62(20):5711-9 [12384529.001]

[Cites] Br J Haematol. 2003 Apr;121(2):287-95 [12694251.001]

[Cites] Exp Hematol. 2003 Sep;31(9):779-83 [12962723.001]

[Cites] Int J Oncol. 2003 Oct;23(4):1055-69 [12963986.001]

[Cites] Exp Cell Res. 1984 Jul;153(1):91-8 [6610562.001]

[Cites] Biochem Biophys Res Commun. 1994 Mar 30;199(3):1209-15 [8147861.001]

[Cites] Lipids. 1997 Mar;32(3):255-62 [9076662.001]

[Cites] Blood. 1998 Aug 15;92(4):1406-14 [9694730.001]

[Cites] Atheroscler Suppl. 2004 Oct;5(3):67-80 [15531278.001]

[Cites] J Clin Invest. 2005 Apr;115(4):959-68 [15776112.001]

[Cites] Blood. 2005 Jul 15;106(2):650-7 [15802535.001]

[Cites] Leukemia. 2005 Jul;19(7):1216-23 [15858619.001]

[Cites] Clin Immunol. 2006 Jul;120(1):76-90 [16473553.001]

[Cites] J Clin Oncol. 2006 Jul 1;24(19):3218-9; author reply 3219-20 [16809747.001]

[Cites] Leuk Lymphoma. 2006 Jun;47(6):1053-61 [16840197.001]

[Cites] J Clin Oncol. 2006 Oct 1;24(28):4634-41 [17008705.001]

[Cites] Leuk Lymphoma. 2006 Dec;47(12):2625-34 [17169808.001]

[Cites] Immunology. 2007 Mar;120(3):315-24 [17140403.001]

[Cites] Cancer Chemother Pharmacol. 2007 Sep;60(4):545-53 [17186240.001]

(PMID = 20496995.001).

[ISSN] 1029-2403

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / K23 CA113408; United States / NCI NIH HHS / CA / CA113408

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 4F4X42SYQ6 / Rituximab

[Other-IDs] NLM/ NIHMS549713; NLM/ PMC3913168

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Case report of synchronous manifestation of two malignant tumors--cervical cancer and malignant lymphoma].

Affected lymph nodes in cervical cancer is different and depends on the stage and histological type of tumor (squamous and adenocarcinoma) and is an important prognostic factor.

Malignant non-Hodgkin's lymphoma populations (NHL) originale from the lymph organs and from their populations downstream lymphoid Stem cell to mature lymphocytes that have opportunities for transformation and proliferation.

We present the random case developed cervical cancer and malignant lymphoma.

[MeSH-major] Lymphoma / pathology. Uterine Cervical Neoplasms / pathology

Genetic Alliance. consumer health - Cervical cancer.

MedlinePlus Health Information. consumer health - Cervical Cancer.

MedlinePlus Health Information. consumer health - Lymphoma.

International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21268405.001).

[ISSN] 0324-0959

[Journal-full-title] Akusherstvo i ginekologii︠a︡

[ISO-abbreviation] Akush Ginekol (Sofiia)

[Language] bul

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Bulgaria

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary manifestation of small lymphocytic lymphoma in the prostate.

BACKGROUND: Infiltration of non-haematopoietic organs by small lymphocytic lymphoma/chronic lymphocytic leukaemia (SLL/CLL) is not unusual in late-stage disease and thus quite frequently encountered in post-mortem examinations.

[MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy

MedlinePlus Health Information. consumer health - Prostate Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2009 S. Karger AG, Basel.

[CommentIn] Onkologie. 2009 Oct;32(10):550-1 [19816069.001]

(PMID = 19816076.001).

[ISSN] 1423-0240

[Journal-full-title] Onkologie

[ISO-abbreviation] Onkologie

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] Switzerland

[Number-of-references] 17

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.

Circulating inflammatory cytokines have a prognostic impact independent of the information provided by the International Prognostic Index (IPI) in diffuse large B-cell lymphoma (DLBCL).

The present study characterized prognostic cytokines in relation to stage-specific B-cell differentiation antigens and bcl-2 protein expression, assessed by immunohistochemistry in de novo DLBCL.

Serum levels of interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-alpha) were found to be significantly lower in patients with a germinal centre (GC) phenotype (co-expression of bcl-6 and CD10) compared with the non-GC phenotype.

However, IL-6 and VEGF, combined with non-GC phenotype and bcl-2 positivity, respectively, had a similar independent prognostic power as the IPI.

In conclusion, our data suggest that inflammatory cytokines are differently distributed in the GC and non-GC phenotypes and correlate to bcl-2 expression.

[MeSH-major] Cytokines / metabolism. DNA-Binding Proteins / metabolism. Lymphoma, B-Cell / blood. Lymphoma, Large B-Cell, Diffuse / blood. Neprilysin / metabolism. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Transcription Factors / metabolism

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15755285.001).

[ISSN] 0007-1048

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Cytokines; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.11 / Neprilysin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Presence of circulating CCR10+ T cells and elevated serum CTACK/CCL27 in the early stage of mycosis fungoides.

PURPOSE: Mycosis fungoides (MF), a common type of cutaneous T cell lymphoma with an indolent clinical course, has the characteristic that malignant T cell clones are recruited into the skin from the early disease stages.

Recently, CCR10 and CTACK/CCL27 were proposed to play a role in the recruitment of other types of cutaneous T cell lymphoma.

Genetic Alliance. consumer health - Mycosis fungoides.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16675558.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / CCL27 protein, human; 0 / CCR10 protein, human; 0 / Chemokine CCL27; 0 / Chemokines, CC; 0 / Receptors, CCR10; 0 / Receptors, Chemokine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma.

OBJECTIVE: To assess serum albumin, total cholesterol, retinol, zinc and hemoglobin in children who had completed treatment for acute lymphoblastic leukemia (ALL) and Non-Hodgkin's lymphoma (NHL).

Comparisons were made to stage of treatment (maintenance 6 with post-therapy), type of treatment (chemotherapy and radiation with only chemotherapy) and type of malignancy (ALL with NHL).

[MeSH-major] Lymphoma, Non-Hodgkin / blood. Nutritional Status. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Trace Elements / blood. Vitamin A / blood. Vitamins / blood

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

Genetic Alliance. consumer health - Acute Non Lymphoblastic Leukemia.

Genetic Alliance. consumer health - Lymphoblastic lymphoma.

MedlinePlus Health Information. consumer health - Vitamin A.

Hazardous Substances Data Bank. CHOLESTEROL .

Hazardous Substances Data Bank. VITAMIN A .

Hazardous Substances Data Bank. ZINC, ELEMENTAL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17353583.001).

[ISSN] 0731-5724

[Journal-full-title] Journal of the American College of Nutrition

[ISO-abbreviation] J Am Coll Nutr

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hemoglobins; 0 / Serum Albumin; 0 / Trace Elements; 0 / Vitamins; 11103-57-4 / Vitamin A; 97C5T2UQ7J / Cholesterol; J41CSQ7QDS / Zinc

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4.

BACKGROUND AND OBJECTIVES: Although most patients with classical Hodgkin's lymphoma (CHL) are cured, a significant minority are refractory to treatment.

The aim of our study was to detect B-cell differentiation markers and transcription factors in CHL in order to define subgroups with different histogeneses and prognoses.

DESIGN AND METHODS: We evaluated 107 cases of CHL for BCL6, CD79a, MUM1/IRF4 and B-cell transcription factors BOB.1, OCT.2 expression by immunohistochemistry.

Univariate analysis showed that age of 45 or more, stage III and IV disease and MUM/IRF4 negative status were associated with significantly shorter time to progression (TTP) and overall survival (OS).

[MeSH-major] Cell Differentiation. Hodgkin Disease / metabolism. Hodgkin Disease / pathology. Interferon Regulatory Factors / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Transcription Factors / metabolism

MedlinePlus Health Information. consumer health - Hodgkin Disease.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17768115.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Journal Article

[Publication-country] Italy

[Chemical-registry-number] 0 / Biomarkers; 0 / Interferon Regulatory Factors; 0 / Transcription Factors; 0 / interferon regulatory factor-4

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The pattern of miRNA expression can be correlated with cancer type, stage, and other clinical variables, so miRNA profiling can be used as a tool for cancer diagnosis and prognosis. miRNA expression analyses also suggest oncogenic (or tumor-suppressive) roles of miRNAs. miRNAs play roles in almost all aspects of cancer biology, such as proliferation, apoptosis, invasion/metastasis, and angiogenesis.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mol Cell Biol. 2007 Mar;27(6):2240-52 [17242205.001]

[Cites] Cancer Res. 2007 Mar 1;67(5):2345-50 [17332367.001]

[Cites] J Biol Chem. 2007 Mar 16;282(11):8256-64 [17220301.001]

[Cites] J Biol Chem. 2005 Apr 29;280(17):16635-41 [15722555.001]

[Cites] J Cell Physiol. 2005 Jul;204(1):280-5 [15648093.001]

[Cites] Trends Genet. 2005 Jun;21(6):322-6 [15922829.001]

[Cites] Immunol Cell Biol. 2007 Aug-Sep;85(6):458-62 [17621315.001]

[Cites] Oncogene. 2007 Sep 6;26(41):6099-105 [17384677.001]

[Cites] Oncogene. 2007 Sep 13;26(42):6133-40 [17404574.001]

[Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]

[Cites] Nat Cell Biol. 2005 Jul;7(7):719-23 [15937477.001]

[Cites] Nat Genet. 2005 Jul;37(7):766-70 [15965474.001]

[Cites] Science. 2005 Jul 8;309(5732):310-1 [15919954.001]

[Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]

[Cites] Science. 2001 Oct 26;294(5543):858-62 [11679671.001]

[Cites] Science. 2001 Oct 26;294(5543):862-4 [11679672.001]

[Cites] Science. 2002 Sep 20;297(5589):2056-60 [12154197.001]

[Cites] Genes Dev. 2002 Oct 1;16(19):2491-6 [12368260.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]

[Cites] Science. 2002 Dec 20;298(5602):2283 [12493874.001]

[Cites] RNA. 2003 Mar;9(3):277-9 [12592000.001]

[Cites] Nature. 2003 Sep 25;425(6956):415-9 [14508493.001]

[Cites] Cell. 2003 Oct 17;115(2):199-208 [14567917.001]

[Cites] Cell. 2003 Oct 17;115(2):209-16 [14567918.001]

[Cites] Mol Cancer Res. 2003 Oct;1(12):882-91 [14573789.001]

[Cites] Genes Chromosomes Cancer. 2004 Feb;39(2):167-9 [14695998.001]

[Cites] Cell. 2003 Dec 26;115(7):787-98 [14697198.001]

[Cites] Genes Dev. 2003 Dec 15;17(24):3011-6 [14681208.001]

[Cites] Science. 2004 Jan 2;303(5654):95-8 [14631048.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]

[Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]

[Cites] Cancer Res. 2004 May 1;64(9):3087-95 [15126345.001]

[Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]

[Cites] Genome Res. 2004 Oct;14(10A):1902-10 [15364901.001]

[Cites] EMBO J. 2004 Oct 13;23(20):4051-60 [15372072.001]

[Cites] Mol Cell Biol. 1989 Jun;9(6):2657-64 [2548084.001]

[Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]

[Cites] Cell. 1993 Dec 3;75(5):855-62 [8252622.001]

[Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]

[Cites] Trends Biochem Sci. 1998 Jun;23(6):198-9 [9644970.001]

[Cites] Nature. 2004 Nov 11;432(7014):235-40 [15531877.001]

[Cites] Nature. 2004 Nov 11;432(7014):231-5 [15531879.001]

[Cites] Nature. 2004 Nov 11;432(7014):226-30 [15538371.001]

[Cites] RNA. 2004 Dec;10(12):1957-66 [15525708.001]

[Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]

[Cites] Cell. 2005 Jan 14;120(1):21-4 [15652478.001]

[Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]

[Cites] Cancer Sci. 2005 Feb;96(2):111-5 [15723655.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]

[Cites] Cell. 2005 Mar 11;120(5):623-34 [15766526.001]

[Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]

[Cites] Nature. 2005 Mar 17;434(7031):338-45 [15735639.001]

[Cites] Cancer Res. 2007 Sep 15;67(18):8433-8 [17823410.001]

[Cites] Cancer Res. 2007 Sep 15;67(18):8699-707 [17875710.001]

[Cites] Blood. 2007 Oct 1;110(7):2631-40 [17586726.001]

[Cites] RNA. 2007 Oct;13(10):1668-74 [17698639.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15484-9 [17855557.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15472-7 [17875987.001]

[Cites] Cancer Res. 2007 Oct 1;67(19):8994-9000 [17908999.001]

[Cites] Dev Biol. 2007 Oct 15;310(2):442-53 [17765889.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15805-10 [17890317.001]

[Cites] Cancer Sci. 2007 Dec;98(12):1845-52 [17888029.001]

[Cites] Cancer Sci. 2007 Dec;98(12):1914-20 [17892514.001]

[Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]

[Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]

[Cites] Cell. 2005 Aug 26;122(4):553-63 [16122423.001]

[Cites] Science. 2005 Sep 2;309(5740):1577-81 [16141076.001]

[Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]

[Cites] J Biol Chem. 2007 Jan 26;282(4):2135-43 [17135249.001]

[Cites] J Biol Chem. 2007 Jan 26;282(4):2130-4 [17135268.001]

[Cites] Int J Cancer. 2007 Mar 1;120(5):1046-54 [17149698.001]

[Cites] Genes Chromosomes Cancer. 2007 Apr;46(4):336-47 [17243163.001]

[Cites] Mol Cell Biol. 2007 Mar;27(5):1859-67 [17194750.001]

[Cites] Cancer Res. 2007 Feb 15;67(4):1419-23 [17308078.001]

[Cites] Cancer Res. 2007 Feb 15;67(4):1424-9 [17308079.001]

[Cites] Leuk Lymphoma. 2007 Feb;48(2):410-2 [17325905.001]

[Cites] Nature. 2005 Dec 1;438(7068):685-9 [16258535.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]

[Cites] Nucleic Acids Res. 2006;34(2):e9 [16434699.001]

[Cites] Cancer Res. 2006 Feb 1;66(3):1277-81 [16452179.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]

[Cites] Gene Ther. 2006 Mar;13(6):496-502 [16195701.001]

[Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3687-92 [16505370.001]

[Cites] Cell. 2006 Mar 24;124(6):1169-81 [16564011.001]

[Cites] Nucleic Acids Res. 2006;34(6):1765-71 [16582102.001]

[Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2014-24 [16609010.001]

[Cites] Oncogene. 2006 Apr 20;25(17):2537-45 [16331254.001]

[Cites] Gene. 2006 May 10;372:137-41 [16503100.001]

[Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092.001]

[Cites] Nature. 2006 May 25;441(7092):537-41 [16724069.001]

[Cites] Endocr Relat Cancer. 2006 Jun;13(2):497-508 [16728577.001]

[Cites] Cell. 2006 Jun 2;125(5):887-901 [16751099.001]

[Cites] Gastroenterology. 2006 Jun;130(7):2113-29 [16762633.001]

[Cites] Cancer Cell. 2006 Jun;9(6):435-43 [16766263.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41 [16754881.001]

[Cites] Cancer Res. 2006 Jun 15;66(12):6097-104 [16778182.001]

[Cites] Nat Genet. 2006 Jul;38(7):813-8 [16751773.001]

[Cites] RNA. 2006 Jul;12(7):1161-7 [16738409.001]

[Cites] Genes Dev. 2006 Aug 15;20(16):2202-7 [16882971.001]

[Cites] Mol Cancer. 2006;5:29 [16854228.001]

[Cites] Nat Genet. 2006 Sep;38(9):1060-5 [16878133.001]

[Cites] J Cell Biol. 2006 Aug 28;174(5):677-87 [16923828.001]

[Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3584-91 [16822819.001]

[Cites] Biochem Biophys Res Commun. 2006 Oct 13;349(1):59-68 [16934749.001]

[Cites] Mol Cancer. 2006;5:24 [16784538.001]

[Cites] Cancer Res. 2006 Sep 15;66(18):9090-8 [16982751.001]

[Cites] J Cell Biochem. 2006 Oct 15;99(3):671-8 [16924677.001]

[Cites] J Clin Oncol. 2006 Oct 10;24(29):4677-84 [16966691.001]

[Cites] Mol Cell Biol. 2006 Nov;26(21):8191-201 [16940181.001]

[Cites] Cancer Res. 2006 Nov 15;66(22):10843-8 [17108120.001]

[Cites] PLoS Biol. 2006 Jul;4(7):e210 [16756390.001]

[Cites] J Cell Physiol. 2007 Feb;210(2):370-7 [17111382.001]

[Cites] Nat Struct Mol Biol. 2006 Dec;13(12):1097-101 [17099701.001]

[Cites] Cancer Res. 2006 Dec 15;66(24):11590-3 [17178851.001]

[Cites] J Virol. 2007 Jan;81(2):1033-6 [17079300.001]

[Cites] J Biol Chem. 2007 Jan 12;282(2):1479-86 [17110380.001]

[Cites] Cell Cycle. 2006 Dec;5(24):2835-8 [17172864.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19983-8 [18056640.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19971-6 [18056805.001]

[Cites] RNA. 2008 Jan;14(1):35-42 [18025253.001]

[Cites] Cancer Res. 2007 Dec 15;67(24):11612-20 [18089790.001]

[Cites] Immunity. 2007 Dec;27(6):825-7 [18093533.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20350-5 [18077375.001]

[Cites] Science. 2007 Dec 21;318(5858):1931-4 [18048652.001]

[Cites] Methods. 2008 Jan;44(1):22-30 [18158129.001]

[Cites] Cancer Res. 2007 Mar 15;67(6):2456-68 [17363563.001]

[Cites] Science. 2007 Mar 16;315(5818):1576-9 [17322030.001]

[Cites] Genome Biol. 2007;8(2):R27 [17326821.001]

[Cites] Retrovirology. 2007;4:5 [17442096.001]

[Cites] Mol Endocrinol. 2007 May;21(5):1132-47 [17312270.001]

[Cites] Nat Genet. 2007 May;39(5):673-7 [17401365.001]

[Cites] Nat Cell Biol. 2005 Jun;7(6):633-6 [15908945.001]

[Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]

[Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]

[Cites] Mol Cancer. 2007;6:5 [17222355.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1604-9 [17242365.001]

[Cites] Cancer Res. 2007 Feb 1;67(3):976-83 [17283129.001]

[Cites] Science. 2001 Aug 3;293(5531):834-8 [11452083.001]

[Cites] Science. 2001 Oct 26;294(5543):853-8 [11679670.001]

[Cites] Methods. 2008 Jan;44(1):31-8 [18158130.001]

[Cites] Cell. 2007 Dec 28;131(7):1273-86 [18155131.001]

[Cites] Genome Biol. 2007;8(8):R166 [17697356.001]

[Cites] Nat Rev Genet. 2008 Feb;9(2):102-14 [18197166.001]

[Cites] Curr Protoc Mol Biol. 2008 Jan;Chapter 26:Unit26.7 [18231982.001]

[Cites] Genome Biol. 2007;8(10):R214 [17922911.001]

[Cites] Oncogene. 2007 Apr 26;26(19):2799-803 [17072344.001]

[Cites] Genes Dev. 2007 May 1;21(9):1025-30 [17437991.001]

[Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]

[Cites] Blood. 2007 May 15;109(10):4399-405 [17284533.001]

[Cites] J Biol Chem. 2007 May 11;282(19):14328-36 [17363372.001]

[Cites] Proc Natl Acad Sci U S A. 2007 May 8;104(19):8017-22 [17470785.001]

[Cites] Proc Natl Acad Sci U S A. 2007 May 8;104(19):7957-62 [17483472.001]

[Cites] Nucleic Acids Res. 2007;35(9):2885-92 [17439965.001]

[Cites] Mol Cell Biol. 2007 Jun;27(11):3970-81 [17403906.001]

[Cites] Nat Rev Genet. 2007 Jun;8(6):413-23 [17486121.001]

[Cites] Mol Cancer Ther. 2007 May;6(5):1483-91 [17483436.001]

[Cites] Blood. 2007 Jun 1;109(11):4944-51 [17327404.001]

[Cites] Drug Discov Today. 2007 Jun;12(11-12):452-8 [17532529.001]

[Cites] Mol Cell Biol. 2007 Jun;27(12):4238-47 [17438130.001]

[Cites] PLoS Pathog. 2007 May 11;3(5):e65 [17500590.001]

[Cites] Oncogene. 2007 May 31;26(26):3769-76 [17173072.001]

[Cites] Cancer Res. 2007 Jun 1;67(11):5148-55 [17545593.001]

[Cites] Neuron. 2007 Jun 7;54(5):813-29 [17553428.001]

[Cites] Science. 2007 Jun 8;316(5830):1484-8 [17510325.001]

[Cites] Mol Cell. 2007 Jun 8;26(5):731-43 [17540598.001]

[Cites] Mol Cell. 2007 Jun 8;26(5):745-52 [17540599.001]

[Cites] World J Gastroenterol. 2007 May 28;13(20):2883-8 [17569129.001]

[Cites] Cancer Res. 2007 Jun 15;67(12):5699-707 [17575136.001]

[Cites] Nature. 2007 Jun 28;447(7148):1130-4 [17554337.001]

[Cites] Oncogene. 2007 Jun 28;26(30):4442-52 [17237814.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10980-5 [17581865.001]

[Cites] Int J Cancer. 2007 Sep 1;121(5):1156-61 [17487835.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11400-5 [17600087.001]

[Cites] Nature. 2007 Jul 5;448(7149):83-6 [17589500.001]

[Cites] Mol Cell. 2007 Jul 6;27(1):91-105 [17612493.001]

[Cites] Cancer Res. 2007 Jul 1;67(13):6031-43 [17616659.001]

[Cites] Cancer Res. 2007 Jul 1;67(13):6092-9 [17616664.001]

[Cites] Cancer Res. 2007 Jul 1;67(13):6130-5 [17616669.001]

[Cites] Cell Cycle. 2007 Jul 1;6(13):1586-93 [17554199.001]

[Cites] J Pathol. 2007 Aug;212(4):368-77 [17471471.001]

[Cites] Oncogene. 2007 Jul 26;26(34):5017-22 [17297439.001]

[Cites] Nucleic Acids Res. 2007;35(13):4535-41 [17584784.001]

[Cites] Nat Genet. 2007 Aug;39(8):1033-7 [17643101.001]

[Cites] Blood. 2007 Aug 15;110(4):1330-3 [17496199.001]

[Cites] J Biol Chem. 2007 Aug 10;282(32):23716-24 [17569667.001]

[Cites] Gastroenterology. 2007 Aug;133(2):647-58 [17681183.001]

[Cites] Curr Biol. 2007 Aug 7;17(15):1298-307 [17656095.001]

[Cites] EMBO J. 2007 Aug 8;26(15):3699-708 [17627278.001]

[Cites] Cancer Sci. 2007 Sep;98(9):1482-90 [17608773.001]

[Cites] Cancer Res. 2007 Aug 15;67(16):7713-22 [17699775.001]

[Cites] Cell Cycle. 2007 Aug 15;6(16):2005-9 [17721077.001]

[Cites] Nat Methods. 2007 Sep;4(9):721-6 [17694064.001]

[Cites] Mol Cell. 2007 Oct 26;28(2):328-36 [17964270.001]

[Cites] Mol Cancer. 2007;6:54 [17716371.001]

[Cites] J Biol Chem. 2007 Nov 9;282(45):32773-9 [17724023.001]

[Cites] PLoS One. 2007;2(11):e1133 [17989771.001]

[Cites] Cancer Res. 2007 Nov 15;67(22):11001-11 [18006846.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19291-6 [18042700.001]

[Cites] Science. 2005 Oct 14;310(5746):317-20 [16224024.001]

[Cites] Leukemia. 2005 Nov;19(11):2013-6 [16167061.001]

[Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]

[Cites] Nat Genet. 2005 Nov;37(11):1163-5 [16254559.001]

[Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]

(PMID = 18817506.001).

[ISSN] 1553-4014

[Journal-full-title] Annual review of pathology

[ISO-abbreviation] Annu Rev Pathol

[Language] ENG

[Grant] United States / NIAMS NIH HHS / AR / AR053948-03; United States / NIAMS NIH HHS / AR / R01 AR053948; United States / NIAMS NIH HHS / AR / AR 053948; United States / NIAMS NIH HHS / AR / R01 AR053948-03

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs

[Number-of-references] 209

[Other-IDs] NLM/ NIHMS153379; NLM/ PMC2769253

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.

QUESTIONS: In patients with multiple myeloma, Waldenström macroglobulinemia, or lymphoma, what is the efficacy of bortezomib alone or in combination as measured by survival, quality of life, disease control (for example, time to progression), response duration, or response rate?What is the toxicity associated with the use of bortezomib?Which patients are more or less likely to benefit from treatment with bortezomib?

No randomized trials were retrieved for lymphoma.

Bortezomib is recommended as the preferred treatment option in patients with myeloma relapsing within 1 year of the conclusion of initial treatment; it may also be a reasonable option in patients relapsing at least 1 year after autologous stem-cell transplantation.

PRACTICE GUIDELINE: This evidence-based series applies to adult patients with myeloma, Waldenström macroglobulinemia, or lymphoma of any type, stage, histology, or performance status.

RECOMMENDATIONS: Based on the results of a large well-conducted rct, which represents the only published randomized study in relapsed myeloma, the Hematology Disease Site Group (dsg) offers the following recommendations: For patients with myeloma refractory to or relapsing within 1 year of the conclusion of initial or subsequent treatment or treatments, including autologous stem-cell transplantation, and who are candidates for further chemotherapy, bortezomib is recommended as the preferred treatment option.Bortezomib is also a reasonable option for patients relapsing at least 1 year after autologous stem-cell transplantation.

However, evaluation of these other options is beyond the scope of this practice guideline.For patients with myeloma relapsing at least 1 year after the conclusion of alkylating agent-based chemotherapy who are candidates for further chemotherapy, further treatment with alkylating agent-based chemotherapy is recommended.Evidence is insufficient to support the use of bortezomib in patients with non-Hodgkin lymphoma or Waldenström macroglobulinemia outside of clinical trials.

The Hematology dsg recognizes that thalidomide is an active agent in multiple myeloma patients who have relapsed after autologous stem-cell transplantation or who are refractory to alkylating agent-based chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Intern Med. 1986 Jul;105(1):8-11 [3717812.001]

[Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]

[Cites] Cancer. 1981 Apr 15;47(8):1923-9 [7226087.001]

[Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]

[Cites] Blood. 2004 Jul 15;104(2):336-9 [15054044.001]

[Cites] Blood. 2004 Aug 1;104(3):607-18 [15090448.001]

[Cites] Blood. 2004 Sep 1;104(5):1386-95 [15155468.001]

[Cites] Br J Haematol. 2004 Oct;127(2):165-72 [15461622.001]

[Cites] Mayo Clin Proc. 2005 Dec;80(12):1578-82 [16342650.001]

[Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]

[Cites] J Clin Oncol. 1998 Mar;16(3):1226-31 [9508211.001]

[Cites] Blood. 2001 Jul 15;98(2):492-4 [11435324.001]

[Cites] Ann Intern Med. 2002 Apr 16;136(8):619-29 [11955031.001]

[Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]

[Cites] N Engl J Med. 1984 May 24;310(21):1353-6 [6546971.001]

(PMID = 22792013.001).

[ISSN] 1198-0052

[Journal-full-title] Current oncology (Toronto, Ont.)

[ISO-abbreviation] Curr Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Canada

[Other-IDs] NLM/ PMC3394599

[Keywords] NOTNLM ; Bortezomib / Velcade / clinical practice guideline / lymphoma / multiple myeloma / systematic review

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.

Here, for the first time, we address the role of TIMP-1 in the pathogenesis of B-cell lymphomas.

An Epstein-Barr virus (EBV)-negative Burkitt lymphoma cell line with ectopic TIMP-1 expression (TIMP-1JD38) was used to identify genes induced/repressed by TIMP-1.

Analysis revealed changes of genes coding for B-cell growth/differentiation, transcription, and cell cycle regulators.

TIMP-1 repressed expression of germinal center (GC) markers CD10, Bcl-6, PAX-5 and up-regulated plasma cell-associated antigens CD138, MUM-1/IRF-4, XBP-1, and CD44, suggesting a plasma cell differentiation.

This incomplete plasmacytic differentiation occurs without altering cell proliferation, and despite c-Myc deregulation, indicating an arrested plasmacytic/plasmablastic stage of differentiation.

Further validation in human lymphoma cell lines and in primary B-cell tumors demonstrated a predominant TIMP-1 expression in tumors with plasmacytic/plasmablastic phenotypes, including multiple myelomas.

[MeSH-major] Burkitt Lymphoma / pathology. Cell Differentiation / physiology. Plasma Cells / pathology. Tissue Inhibitor of Metalloproteinase-1 / physiology

[MeSH-minor] B-Lymphocytes / cytology. B-Lymphocytes / enzymology. B-Lymphocytes / metabolism. Cell Cycle Proteins / antagonists & inhibitors. Cell Cycle Proteins / biosynthesis. Cell Line, Tumor. Cell Proliferation. Down-Regulation / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / physiology. Humans. Lymphoid Tissue / enzymology. Lymphoid Tissue / pathology. Lymphoma, B-Cell / enzymology. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Multiple Myeloma / enzymology. Multiple Myeloma / genetics. Oligonucleotide Array Sequence Analysis. Repressor Proteins / physiology. Transcription Factors / antagonists & inhibitors. Transcription Factors / biosynthesis. Transcription, Genetic / physiology. Up-Regulation / genetics

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15479729.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Validation Studies

[Publication-country] United States

[Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Repressor Proteins; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Transcription Factors

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa.

Hodgkin's disease (HD) in children corresponds to a large degree to HD in adults.

Non-Hodgkin's Lymphoma (NHL) in children, however, differs from NHL in adults with respect to the classification, natural history, management and course.

For practical reasons clinicians generally classify and treat NHL in children as either B-cell or T-cell disease.

Lymphoblastic or T-cell NHL is treated with regimens normally used for acute lymphoblastic leukaemia (e.g.

BFM protocols) or modified leukaemia treatments for leukaemia-lymphoma syndromes (e.g. LSA2L2).

Three consecutive regimens have been used to treat B-cell NHL over the past 22 years.

Although toxicity has increased with the increased intensity of the treatment regimen, EFS has improved from 25% to 87% for all B-cell NHL.

The majority of patients had stage III and IV disease.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy

MedlinePlus Health Information. consumer health - Hodgkin Disease.

Hazardous Substances Data Bank. BLEOMYCIN .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .

Hazardous Substances Data Bank. DACARBAZINE .

Hazardous Substances Data Bank. MECHLORETHAMINE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .

Hazardous Substances Data Bank. VINCRISTINE .

Hazardous Substances Data Bank. PROCARBAZINE .

Hazardous Substances Data Bank. VINBLASTINE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15737871.001).

[ISSN] 1473-0502

[Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

[ISO-abbreviation] Transfus. Apher. Sci.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol

[Number-of-references] 15

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Investigational strategies in autologous stem cell transplantation for follicular lymphoma.

Recent retrospective analyses indicate prolonged survival for patients with follicular lymphoma over the past 25 years, attributed most likely to improved supportive care and sequential application of effective therapies.

Encouraging results were obtained from several randomized trials evaluating myeloablative therapy followed by autologous stem cell transplantation (ASCT) as consolidation therapy applied to patients with advanced-stage follicular lymphoma either in first remission or as salvage therapy.

Combination of these novel strategies into a multimodal approach justifies hope that the treatment outcome of patients suffering from follicular lymphoma will be further improved.

[MeSH-major] Clinical Trials as Topic. Hematopoietic Stem Cell Transplantation. Lymphoma, Follicular / therapy

Genetic Alliance. consumer health - Follicular Lymphoma.

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Clinical Trials.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2005 Aug 1;23(22):5019-26 [15983392.001]

[Cites] J Clin Oncol. 2004 Dec 15;22(24):4926-33 [15611507.001]

[Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]

[Cites] J Clin Oncol. 1997 Feb;15(2):445-50 [9053464.001]

[Cites] Blood. 2005 May 15;105(10):3817-23 [15687232.001]

[Cites] Blood. 2000 Nov 1;96(9):2934-42 [11049969.001]

[Cites] Blood. 1984 Jun;63(6):1424-33 [6609729.001]

[Cites] J Clin Oncol. 2003 Nov 1;21(21):3918-27 [14517188.001]

[Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]

[Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]

[Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]

[Cites] J Clin Oncol. 2004 Apr 15;22(8):1460-8 [15084619.001]

[Cites] Blood. 2000 Aug 1;96(3):864-9 [10910898.001]

[Cites] Blood. 2006 Sep 1;108(5):1504-8 [16690968.001]

[Cites] Bone Marrow Transplant. 2003 Aug;32(3):317-24 [12858205.001]

[Cites] Radiother Oncol. 2000 Jul;56(1):1-8 [10869748.001]

[Cites] Blood. 1995 Jun 1;85(11):3334-41 [7538824.001]

[Cites] Blood. 2003 Oct 1;102(7):2351-7 [12750161.001]

[Cites] Blood. 2003 Nov 15;102(10):3521-9 [12893748.001]

[Cites] Int J Radiat Biol Relat Stud Phys Chem Med. 1982 Apr;41(4):411-20 [7042622.001]

[Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6 [2456618.001]

[Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]

[Cites] Blood. 2005 Oct 15;106(8):2896-902 [16002426.001]

[Cites] Blood. 1987 Feb;69(2):584-91 [3492224.001]

[Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]

[Cites] J Clin Oncol. 2000 Mar;18(5):947-55 [10694543.001]

[Cites] J Clin Oncol. 1997 Mar;15(3):1110-7 [9060552.001]

[Cites] Blood. 2004 Nov 1;104(9):2667-74 [15238420.001]

[Cites] Lancet Oncol. 2004 Dec;5(12):711-7 [15581541.001]

[Cites] J Clin Oncol. 2000 Feb;18(3):527-36 [10653868.001]

[Cites] Blood. 1999 Nov 15;94(10):3325-33 [10552941.001]

[Cites] J Immunol. 1985 Aug;135(2):973-9 [3925015.001]

[Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]

[Cites] J Clin Oncol. 2005 Jan 20;23 (3):461-7 [15534357.001]

[Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]

[Cites] Bone Marrow Transplant. 2003 Jul;32(1):57-63 [12815479.001]

[Cites] Semin Oncol. 2003 Apr;30(2 Suppl 4):10-21 [12728403.001]

[Cites] Semin Oncol. 1993 Oct;20(5 Suppl 5):75-88 [8211209.001]

(PMID = 16901398.001).

[ISSN] 1523-3790

[Journal-full-title] Current oncology reports

[ISO-abbreviation] Curr Oncol Rep

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal

[Number-of-references] 48

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Follicular lymphoma of the thyroid gland.

The majority of lymphomas arising in the thyroid gland are mucosa-associated lymphoid tissue lymphomas and diffuse large B-cell lymphomas, which arise from a background of chronic lymphocytic thyroiditis.

Follicular lymphoma may also present in the thyroid gland, but its clinicopathologic features at this site are not well characterized, leading to difficulties in diagnosis and clinical management.

All cases showed morphology characteristic of follicular lymphoma, however, in many the interfollicular neoplastic infiltrate was particularly prominent and all lymphomas contained readily identifiable and often striking lymphoepithelial lesions, features heretofore considered indicative of mucosa-associated lymphoid tissue lymphoma at this site.

In 1 group, similar to typical adult follicular lymphoma, cases carried a t(14;18)/IGH-BCL2 and/or expressed Bcl-2, and were mostly CD10-positive and of World Health Organization (WHO) grade 1 to 2.

The 2 groups differed in clinical stage at presentation, 11 patients in the former group but none in the latter group having disease beyond the thyroid gland.

Appreciation of the spectrum of morphologic, immunophenotypic, and genetic characteristics of follicular lymphoma presenting in the thyroid gland should aid both diagnosis and clinical management.

Genetic Alliance. consumer health - Follicular Lymphoma.

Genetic Alliance. consumer health - Thyroid Lymphoma.

MedlinePlus Health Information. consumer health - Thyroid Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Trends Immunol. 2008 Jan;29(1):25-33 [18061541.001]

[Cites] J Clin Oncol. 1999 Apr;17(4):1254 [10561186.001]

[Cites] Am J Surg Pathol. 2000 May;24(5):623-39 [10800981.001]

[Cites] Am J Surg Pathol. 2000 Jun;24(6):846-52 [10843287.001]

[Cites] Blood. 2000 Jun 15;95(12):3922-8 [10845929.001]

[Cites] Histopathology. 2000 Jul;37(1):10-8 [10931213.001]

[Cites] Cancer. 2001 Feb 15;91(4):629-35 [11241227.001]

[Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):105-11 [11788631.001]

[Cites] Am J Surg Pathol. 2002 Feb;26(2):216-24 [11812943.001]

[Cites] J Clin Oncol. 2002 Feb 1;20(3):647-55 [11821444.001]

[Cites] Leukemia. 2002 Nov;16(11):2309-17 [12399977.001]

[Cites] Virchows Arch. 2002 Dec;441(6):614-7 [12461620.001]

[Cites] Int J Surg Pathol. 2001 Oct;9(4):287-93 [12574844.001]

[Cites] Blood. 2003 Mar 15;101(6):2335-9 [12406890.001]

[Cites] Blood. 2003 Apr 1;101(7):2489-95 [12456507.001]

[Cites] Ann Oncol. 2003 Apr;14(4):623-9 [12649111.001]

[Cites] Blood. 2003 Aug 1;102(3):1012-8 [12676782.001]

[Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]

[Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]

[Cites] Histopathology. 2004 Mar;44(3):268-76 [14987231.001]

[Cites] Curr Treat Options Oncol. 2004 Aug;5(4):307-13 [15233907.001]

[Cites] Nat Rev Cancer. 2004 Aug;4(8):644-53 [15286744.001]

[Cites] Leukemia. 2004 Oct;18(10):1722-6 [15356642.001]

[Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]

[Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]

[Cites] Histopathology. 1978 May;2(3):201-13 [580930.001]

[Cites] Cancer. 1979 Aug;44(2):529-42 [383257.001]

[Cites] Virchows Arch A Pathol Anat Histol. 1979 Aug 23;383(3):293-317 [158873.001]

[Cites] Am J Clin Pathol. 1980 Jul;74(1):1-11 [7395811.001]

[Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]

[Cites] N Engl J Med. 1985 Mar 7;312(10):601-4 [3838363.001]

[Cites] Histopathology. 1985 Jan;9(1):81-97 [3884481.001]

[Cites] Cancer. 1986 Jul 1;58(1):100-4 [3708539.001]

[Cites] Hum Pathol. 1988 Nov;19(11):1315-26 [3141260.001]

[Cites] Blood. 1991 Aug 1;78(3):581-5 [1859876.001]

[Cites] Eur J Cancer. 1991;27(10):1201-8 [1835586.001]

[Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):929-33 [1555984.001]

[Cites] Am J Pathol. 1992 Jul;141(1):43-52 [1632470.001]

[Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6770-4 [1495966.001]

[Cites] J Exp Med. 1992 Oct 1;176(4):1137-48 [1402658.001]

[Cites] Histopathology. 1994 Apr;24(4):323-7 [8045521.001]

[Cites] J Clin Oncol. 1995 Jan;13(1):140-7 [7799014.001]

[Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]

[Cites] Histopathology. 1996 Jan;28(1):25-32 [8838117.001]

[Cites] Blood. 1998 Jun 15;91(12):4708-14 [9616169.001]

[Cites] Mod Pathol. 1998 Sep;11(9):864-9 [9758366.001]

[Cites] Cell. 1999 Jan 8;96(1):35-45 [9989495.001]

[Cites] Cancer. 1999 Apr 1;85(7):1626-35 [10193956.001]

[Cites] Blood. 1999 Jun 1;93(11):3601-9 [10339464.001]

[Cites] Semin Oncol. 1999 Jun;26(3):316-23 [10375088.001]

[Cites] Am J Clin Pathol. 1999 Aug;112(2):263-70 [10439808.001]

[Cites] Am J Surg Pathol. 2005 Jan;29(1):69-82 [15613857.001]

[Cites] J Pathol. 2005 Feb;205(3):329-35 [15682435.001]

[Cites] J Pathol. 2005 Feb;205(3):293-301 [15682443.001]

[Cites] Best Pract Res Clin Haematol. 2005 Mar;18(1):1-10 [15694181.001]

[Cites] Int J Surg Pathol. 2005 Jan;13(1):73-8 [15735858.001]

[Cites] Leukemia. 2005 Apr;19(4):652-8 [15703784.001]

[Cites] Leukemia. 2005 Jun;19(6):1058-63 [15815725.001]

[Cites] J Clin Oncol. 2005 Sep 10;23(26):6358-63 [16155020.001]

[Cites] Am J Surg Pathol. 2006 Apr;30(4):529-36 [16625101.001]

[Cites] Histopathology. 2006 Sep;49(3):229-41 [16918969.001]

[Cites] Histopathology. 2006 Oct;49(4):426-9 [16978207.001]

[Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]

[Cites] Am J Surg Pathol. 2007 Feb;31(2):170-84 [17255761.001]

[Cites] Blood. 2007 Apr 1;109(7):3076-9 [17138820.001]

[Cites] Am J Surg Pathol. 2007 Jul;31(7):1050-8 [17592272.001]

(PMID = 18830125.001).

[ISSN] 1532-0979

[Journal-full-title] The American journal of surgical pathology

[ISO-abbreviation] Am. J. Surg. Pathol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P50 CA097274-069001; United States / NCI NIH HHS / CA / P50 CA097274-079001; United States / NCI NIH HHS / CA / CA097274-069001; United States / NCI NIH HHS / CA / CA097274-079001; United Kingdom / Wellcome Trust / /

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ NIHMS80966; NLM/ PMC2673478

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Secondary pancreatic involvement by a diffuse large B-cell lymphoma presenting as acute pancreatitis.

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin's lymphoma.

However, a diffuse large B-cell lymphoma presenting as acute pancreatitis is rare.

Biopsy of the axillary mass revealed a large B-cell lymphoma.

The patient was classified as stage IV, based on the Ann Arbor Classification, and as having a high-risk lymphoma, based on the International Prognostic Index.

A literature search revealed only seven cases of primary involvement of the pancreas in B-cell lymphoma presenting as acute pancreatitis.

However, only one case of secondary pancreatic involvement by B-cell lymphoma presenting as acute pancreatitis has been published.

[MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / etiology

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

Genetic Alliance. consumer health - Pancreatitis.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

MedlinePlus Health Information. consumer health - Pancreatitis.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17828824.001).

[ISSN] 1007-9327

[Journal-full-title] World journal of gastroenterology

[ISO-abbreviation] World J. Gastroenterol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Other-IDs] NLM/ PMC4611771

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis.

Late-onset neutropenia, i.e. an absolute neutrophil count of <1.5 x 10(9)/l, may follow 4 weeks or more after therapy with rituximab for lymphoma.

In a retrospective study of 113 consecutive lymphoma patients treated with rituximab, with or without chemotherapy, we found eight patients (7%) with late-onset neutropenia (LON).

Four of the eight patients underwent stem cell transplantation.

In four subsequently identified patients with severe LON, a maturation arrest at the (pro)myelocyte stage was observed in the bone marrow, similar to that found in severe congenital neutropenia or Kostmann disease.

[MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Cell Differentiation / drug effects. DNA Mutational Analysis. Female. Humans. Lymphoma / drug therapy. Male. Middle Aged. Proteins / genetics. Rituximab. Time

Hazardous Substances Data Bank. RITUXIMAB .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Semin Hematol. 2002 Apr;39(2):113-20 [11957194.001]

[Cites] Eur J Haematol Suppl. 2007 Jan;(67):5-14 [17206982.001]

[Cites] Eur J Haematol Suppl. 1996;60:93-7 [8987249.001]

[Cites] Haematologica. 2007 Feb;92(2):e20-3 [17405749.001]

[Cites] Int J Hematol. 2006 Oct;84(3):242-7 [17050199.001]

[Cites] Biol Blood Marrow Transplant. 2000;6(6):628-32 [11128813.001]

[Cites] Acta Paediatr. 2007 Jun;96(6):813-9 [17537008.001]

[Cites] Ann Pharmacother. 2005 Dec;39(12):2091-5 [16249269.001]

[Cites] Autoimmun Rev. 2006 Jan;5(1):18-24 [16338207.001]

[Cites] Curr Drug Metab. 2006 Apr;7(3):219-29 [16611018.001]

[Cites] Blood. 2005 Aug 1;106(3):795-802 [15718416.001]

[Cites] Br J Haematol. 2003 Jun;121(6):913-8 [12786803.001]

[Cites] J Immunol. 2005 Jul 15;175(2):1232-8 [16002727.001]

[Cites] Haematologica. 2004 Mar;89(3):361-3 [15020279.001]

[Cites] Acta Paediatr. 2006 Dec;95(12):1526-32 [17129957.001]

[Cites] Leuk Lymphoma. 2006 Jun;47(6):1013-7 [16840190.001]

[Cites] Leuk Res. 2002 Jun;26(6):597-600 [12007508.001]

[Cites] Bull Cancer. 2007 Feb;94(2):198-202 [17337389.001]

[Cites] Cancer Treat Rev. 2005 Oct;31(6):456-73 [16054760.001]

[Cites] Nature. 1996 Aug 15;382(6592):635-8 [8757135.001]

[Cites] Semin Hematol. 2006 Jul;43(3):189-95 [16822461.001]

[Cites] Blood. 2004 May 1;103(9):3355-61 [14764541.001]

[Cites] Bone Marrow Transplant. 2004 May;33(9):921-3 [15034544.001]

[Cites] Nat Genet. 2007 Jan;39(1):86-92 [17187068.001]

[Cites] Br J Haematol. 2005 Apr;129(2):275-8 [15813856.001]

[Cites] Ann Oncol. 2007 Feb;18(2):364-9 [17079695.001]

[Cites] N Engl J Med. 2003 Jun 26;348(26):2691-4; discussion 2691-4 [12826650.001]

(PMID = 18278570.001).

[ISSN] 1357-0560

[Journal-full-title] Medical oncology (Northwood, London, England)

[ISO-abbreviation] Med. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / HAX1 protein, human; 0 / Proteins; 4F4X42SYQ6 / Rituximab

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In vitro studies indicate that Tiam1 localizes to adherens junctions and plays a role in the formation and maintenance of cadherin-based cell adhesions, thereby regulating migration of epithelial cells.

This two-stage carcinogenesis protocol allows us to study initiation, promotion, and progression of tumors in a Tiam1-positive and Tiam1-negative background.

Moreover, we describe methods to study the role of Tiam1 in susceptibility to apoptosis, cell growth, and Ras transformation by in vivo and in vitro experiments.

[MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Animals. Apoptosis / physiology. Cell Separation. Down-Regulation. Keratinocytes / cytology. Mice. Mice, Knockout. NIH 3T3 Cells. Skin Neoplasms / etiology. Skin Neoplasms / pathology

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16757331.001).

[ISSN] 0076-6879

[Journal-full-title] Methods in enzymology

[ISO-abbreviation] Meth. Enzymol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Guanine Nucleotide Exchange Factors; 0 / Tiam1 protein, mouse; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; EC 3.6.5.2 / ras Proteins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells].

BACKGROUND AND OBJECTIVE: In patients with follicular lymphoma and mantle cell lymphoma circulating lymphoma cells can be detected by quantitative real-time PCR with a high sensitivity and reproducibility.

With this study we wanted to ascertain whether a continuous molecular remission achieved in patients with mantle cell lymphoma and follicular lymphoma has an impact on survival of these patients.

PATIENT AND METHODS: We conducted these investigations in 32 patients (24 with follicular lymphoma and 8 with mantle cell lymphoma) who were treated in a randomized trial with chemotherapy plus/minus rituximab (MCP, R-MCP).

A further ten patients had follicular lymphoma (stage I and II) in long-term complete remission after radiation therapy.

RESULTS: Up to 18 years after initial diagnoses of a stage I or II follicular lymphoma circulating t(14;18) positive cells could be detected in the peripheral blood.

In advanced stage follicular lymphoma patients molecular remissions could only be achieved when they were treated with combined chemo-immunotherapy (MCP+R).

In contrast, the frustrating clinical results obtained from the treatment of patients with mantle cell lymphoma corresponded to an achievement of only short molecular remissions in very few patients.

CONCLUSIONS: The consequent application of quantitative real-time PCR will further improve current treatment strategies in lymphoma patients.

[MeSH-major] Lymphoma, Follicular / pathology. Lymphoma, Mantle-Cell / pathology. Neoplasm, Residual / diagnosis. Neoplastic Cells, Circulating. Polymerase Chain Reaction / methods

Genetic Alliance. consumer health - Follicular Lymphoma.

Genetic Alliance. consumer health - Mantle cell lymphoma.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16172952.001).

[ISSN] 0012-0472

[Journal-full-title] Deutsche medizinische Wochenschrift (1946)

[ISO-abbreviation] Dtsch. Med. Wochenschr.

[Language] ger

[Publication-type] English Abstract; Journal Article

[Publication-country] Germany

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Thymic epithelial cells expressed unusual follicular dendritic cell markers: thymic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

Described herein is a case of thymic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

Using immunohistochemical double staining it was found that most of the thymic lymphoid follicles in this case possessed cytokeratin-positive and follicular dendritic cell (FDC) marker-positive cells.

The present case indicates a possibility that some thymic epithelial cells become FDC, although it was uncertain whether they were derived from the epithelia of Hassall's corpuscles or whether they were at the same differentiation stage as Hassall's corpuscles.

[MeSH-major] Dendritic Cells, Follicular / metabolism. Lymphoma, B-Cell, Marginal Zone / metabolism. Thymus Gland / metabolism. Thymus Neoplasms / metabolism

Genetic Alliance. consumer health - Follicular Lymphoma.

MedlinePlus Health Information. consumer health - Thymus Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18477221.001).

[ISSN] 1440-1827

[Journal-full-title] Pathology international

[ISO-abbreviation] Pathol. Int.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Australia

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Complement 3d

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

A preoperative diagnosis of myeloproliferative disorder was made and it was surgically resected and cranioplasty with porous polyethylene sheets (Medpor, Porex Surgical Inc, GA) was performed in the same stage.

[MeSH-major] Bone Cysts, Aneurysmal / diagnosis. Bone Cysts, Aneurysmal / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19636268.001).

[ISSN] 1536-3678

[Journal-full-title] Journal of pediatric hematology/oncology

[ISO-abbreviation] J. Pediatr. Hematol. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] T-cell lymphoma of the rectum in a patient with AIDS and hepatitis C: a case report and discussion.

Primary T-cell non-Hodgkin's lymphoma (NHL) occurring in the context of acquired immune deficiency syndrome (AIDS) is uncommon.

Although typical in some respects, the case is, in other ways, somewhat unusual for an AIDS-related NHL (ARL); ARL tends to be B cell and advanced stage and our case was T cell and stage IE.

Although this has largely been mitigated by the advent of highly active antiretroviral therapy, our patient eventually suffered complications of chemotherapy, apparently related more to his liver disease than to either his lymphoma or AIDS, that ultimately brought about his demise.

[MeSH-major] AIDS-Related Opportunistic Infections / complications. Hepatitis C / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, T-Cell / diagnosis. Rectal Neoplasms / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Hepatitis.

MedlinePlus Health Information. consumer health - Hepatitis C.

MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15821249.001).

[ISSN] 1083-7159

[Journal-full-title] The oncologist

[ISO-abbreviation] Oncologist

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.

BACKGROUND: The objective of this study was to test a low dose of (25 mg weekly) of the mammalian target of rapamycin kinase inhibitor temsirolimus for patients with relapsed mantle cell lymphoma (MCL).

The median age was 69 years (range, 51-85 years), 86% of patients had stage IV disease, and 71% had > or = 2 extranodal sites.

Genetic Alliance. consumer health - Mantle cell lymphoma.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. SIROLIMUS .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2008 American Cancer Society

[Cites] Curr Treat Options Oncol. 2006 Jul;7(4):285-94 [16916489.001]

[Cites] J Cancer Res Clin Oncol. 2006 Feb;132(2):105-12 [16088404.001]

[Cites] Ann Oncol. 2007 Jan;18(1):116-21 [16971665.001]

[Cites] Leukemia. 2007 Feb;21(2):333-9 [17136116.001]

[Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]

[Cites] Leuk Lymphoma. 2007 Jul;48(7):1299-306 [17613757.001]

[Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5291-4 [17875757.001]

[Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]

[Cites] J Clin Oncol. 2004 Mar 1;22(5):909-18 [14990647.001]

[Cites] Leuk Lymphoma. 2004 Sep;45(9):1821-7 [15223642.001]

[Cites] Blood. 2004 Oct 15;104(8):2269-71 [15166030.001]

[Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]

[Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]

[Cites] J Clin Oncol. 2005 May 20;23(15):3383-9 [15908650.001]

[Cites] J Clin Oncol. 2005 Aug 10;23(23):5347-56 [15983389.001]

[Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]

(PMID = 18543327.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / U10 CA035267; United States / NCI NIH HHS / CA / CA112904; United States / NCI NIH HHS / CA / CA97274; United States / NCI NIH HHS / CA / CA-35090; United States / NCI NIH HHS / CA / U10 CA060276; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / U10 CA037404; United States / NCI NIH HHS / CA / U10 CA035448; United States / NCI NIH HHS / CA / U10 CA063848; United States / NCI NIH HHS / CA / U10 CA035195; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-37403; United States / PHS HHS / / CS-35431; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / U10 CA035101; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / U10 CA035415; United States / NCI NIH HHS / CA / CA-63826; United States / NCI NIH HHS / CA / R21 CA112904; United States / NCI NIH HHS / CA / CA-35415; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-35267; United States / NCI NIH HHS / CA / N01 CA015083

[Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 624KN6GM2T / temsirolimus; W36ZG6FT64 / Sirolimus

[Other-IDs] NLM/ NIHMS454018; NLM/ PMC3627208

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Systemic non-Hodgkin's lymphoma involving the orbit and leptomeninges.

We report a case of diffuse large B-cell lymphoma in a 46-year-old female presenting in an unusual manner with stage IVB disease including concurrent orbital and leptomeningeal involvement.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Br J Ophthalmol. 2001 Jan;85(1):63-9 [11133714.001]

[Cites] Invest Ophthalmol Vis Sci. 2002 Jan;43(1):9-14 [11773006.001]

[Cites] Clin Experiment Ophthalmol. 2001 Dec;29(6):387-93 [11778809.001]

[Cites] Eye (Lond). 2003 Oct;17(7):809-20 [14528242.001]

[Cites] Graefes Arch Clin Exp Ophthalmol. 2004 Feb;242(2):130-45 [14685876.001]

[Cites] Ophthalmology. 2004 May;111(5):997-1008 [15121380.001]

[Cites] Cancer. 1985 May 1;55(9):1907-12 [3872159.001]

[Cites] Am J Pathol. 1999 May;154(5):1449-52 [10329598.001]

[Cites] Ophthal Plast Reconstr Surg. 2005 May;21(3):177-88 [15942490.001]

[Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):597-609, v [16083825.001]

[Cites] Curr Opin Ophthalmol. 2006 Dec;17(6):523-31 [17065920.001]

[Cites] Am J Surg Pathol. 2007 Feb;31(2):170-84 [17255761.001]

[Cites] Arch Ophthalmol. 2007 Dec;125(12):1663-7 [18071119.001]

[Cites] Eye (Lond). 2010 Jun;24(6):954-61 [19942938.001]

(PMID = 23362375.001).

[Journal-full-title] Digital journal of ophthalmology : DJO

[ISO-abbreviation] Digit J Ophthalmol

[Language] ENG

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC3516149